• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Pathogenesis of Ovarian Serous Carcinoma as the Basis for Immunologic Directed Diagnosis and Treatment. Project 2 - Identification of Autologous Antigens in Early Stage Serous Carcinoma
【24h】

Pathogenesis of Ovarian Serous Carcinoma as the Basis for Immunologic Directed Diagnosis and Treatment. Project 2 - Identification of Autologous Antigens in Early Stage Serous Carcinoma

机译：卵巢浆液性癌的发病机制是免疫定向诊断和治疗的基础。项目2 - 早期浆液性癌中自体抗原的鉴定

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Our goal is to develop an early detection screening test for serous carcinoma. Specific aim 1: Obtain cDNAs of autologous tumor antigens recognized by sera of patients with early stage serous carcinoma, but not controls. Progress: While our ovarian cancer cDNA library is construction for SEREX analysis, we have developed an alternative, complementary methodology. We employed patient sera to immunoprecipitate proteins from autologous cancer cells and identified these antigens by mass spectrometry. One antigen, SMAP-1, has homology to genes that facilitate cell division. Specific aim 2: Identify autologous tumor antigens expressed in serous carcinoma but absent from, or a low level in normal tissue. Progress: We have expressed recombinant SMAP-1 protein and generated specific antisera. We the SMAP-1 mRNA is ubiquitous in all tissues tested thus far, and immunohistochemical studies are currently underway. We have already several identified several other SEREX antigens, including the homeobox HOXB7 transcription factor. We have generated peptide antiserum to HOXB7 and confirmed its over expression in cancer cell lines. Interestingly, we also note a shift from a nuclear localization in normal tissue to the cytoplasm in most carcinomas.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号